Home World News Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from... World News Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC By Ogkologos - September 8, 2026 119 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NSABP B-59/GeparDouze study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR COVID-19: “We’ve got so much on our plates” August 4, 2020 No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer... September 9, 2021 Deaths from Metastatic Melanoma Drop Substantially in the United States April 21, 2020 Efficacy of Rituximab Maintenance in Patients with Mantle Cell Lymphoma Who... November 28, 2023 Load more HOT NEWS FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate... Darolutamide in Combination with ADT and Docetaxel Increases Overall Survival in... El cáncer en mi comunidad: Cómo superar las desigualdades en la... Dogs Can Sniff Out COVID-19 After Just One Week Of Training,...
